US58933Y1055
© BusinessWire
24.02.2025
MRK
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (NYSE: MRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Perio...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
MRK
LISTED
NYSE
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Con...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
MRK
LISTED
NYSE
Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (NYSE: MRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.
IF YOU A...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
20.02.2025
MRK
LISTED
NYSE
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MERCK & CO (M...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.02.2025
MRK
LISTED
NYSE
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MERCK & CO (MRK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CL...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
MRK
LISTED
NYSE
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MERCK & CO (MRK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
MRK
LISTED
NYSE
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for:
The treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy...
Themefolio
Profiler
Peergroup
© BusinessWire
17.02.2025
MRK
LISTED
NYSE
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or “the Company”) (NYSE: MRK) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged vio...
Themefolio
Profiler
Peergroup
© BusinessWire
17.02.2025
MRK
LISTED
NYSE
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit. Captioned Cronin v. Merck & Co.,...
Themefolio
Profiler
Peergroup
© BusinessWire
15.02.2025
MRK
LISTED
NYSE
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. (“Merck” or “the Company”) (NYSE: MRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Invest...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
MRK
LISTED
NYSE
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit. Captioned Cronin v....
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
MRK
LISTED
NYSE
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022, and February 3, 2025. Merck describes itself as a “global healthcare company that operates through two segments, Pharmaceutical and Animal Health,...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.02.2025
MRK
LISTED
NYSE
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Merck & Co. Inc. (NYSE: MRK) resulting from allegations that Merck may have issued materially misleading business information to the investing public.
So What: If you purchased Merck securities you ma...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
MRK
LISTED
NYSE
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and p...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
MRK
LISTED
NYSE
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
News Preview
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024.
“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of WINREVAIR and...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
MRK
LISTED
NYSE
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediat...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
MRK
LISTED
NYSE
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the second quarter of 2025. Payment will be made on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. The Boar...
Themefolio
Profiler
Peergroup
© BusinessWire
27.01.2025
MRK
LISTED
NYSE
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) seeking approval of WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult and...
Themefolio
Profiler
Peergroup
© BusinessWire
24.01.2025
MRK
LISTED
NYSE
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, in combination with chemo...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
MRK
LISTED
NYSE
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 4. During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outl...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
MRK
LISTED
NYSE
Merck’s GARDASIL® Receives Expanded Approval for Males in China
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) of China approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases....
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
MRK
LISTED
NYSE
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
MRK
LISTED
NYSE
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299.
Merck will record a pre-tax...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
MRK
LISTED
NYSE
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection that is virologically suppressed on different antiretro...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
MRK
LISTED
NYSE
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
“We continue to leverage science-driven busines...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
MRK
LISTED
NYSE
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), the company’s investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
MRK
LISTED
NYSE
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA®) in the KeyVi...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
MRK
LISTED
NYSE
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after s...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the conditional approval of WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monothera...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
MRK
LISTED
NYSE
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
News Preview
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
MRK
LISTED
NYSE
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA® (pembrolizumab) plus chemotherapy followed by maintenance with LYNPARZA® (olaparib), with or without bevacizumab, as a first-line treatment for people with BRCA non-mutated advanced epithelial ovarian can...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
MRK
LISTED
NYSE
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck’s investigational antibody drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), in combination with cyclophosphamide,...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
MRK
LISTED
NYSE
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the Phase 3 MOVe-NOW clinical trial to evaluate LAGEVRIOTM (molnupiravir), an investigational oral antiviral COVID-19 medicine, for the treatment of adults with COVID-19 at high risk for disease progression. This double-blind, placebo-control...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
MRK
LISTED
NYSE
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with epidermal growth fa...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
MRK
LISTED
NYSE
Merck to Participate in the Citi 2024 Global Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Citi 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
MRK
LISTED
NYSE
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
MRK
LISTED
NYSE
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
News Preview
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited “mini-tender” offer, dated November 12, 2024, to purchase up to 1,000,000 shares of Merck common stock at $96.38 per share. The offer price is approximately 4.32% below the closi...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
MRK
LISTED
NYSE
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
MRK
LISTED
NYSE
Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) in China has approved WELIREG® (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system...
Themefolio
Profiler
Peergroup
© BusinessWire
22.11.2024
MRK
LISTED
NYSE
Surendralal Karsanbhai Elected to Merck Board of Directors
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that Surendralal L. “Lal” Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR), will join Merck’s board of directors effective January 1, 2025. He will stand for election by the company’s shareholders in May 2025. With the additi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
MRK
LISTED
NYSE
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will sho...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
MRK
LISTED
NYSE
Merck Announces First-Quarter 2025 Dividend
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024.
About Mer...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
MRK
LISTED
NYSE
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahyaluroni...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for t...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
MRK
LISTED
NYSE
Merck to Participate in the Jefferies London Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies London...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
MRK
LISTED
NYSE
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNo...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
MRK
LISTED
NYSE
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
News Preview
Alexion, AstraZeneca Rare Disease and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KOMET trial, which is the largest, global randomized double-blind placebo-controlled multicenter Phase 3 trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, i...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
MRK
LISTED
NYSE
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), evaluating the burden and incidence of certain HPV-related cancers and diseases, will be prese...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
MRK
LISTED
NYSE
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
News Preview
KIRKLAND, QC, Nov. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR® (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
MRK
LISTED
NYSE
Merck to Participate in the UBS Global Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of general medicine, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the UBS Global Healthca...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
MRK
LISTED
NYSE
Merck Announces Third-Quarter 2024 Financial Results
News Preview
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2024.
“Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond," said Robert M. Davis, chairman and chief executive officer, Merck. "Our pipeline is advancing and expanding, d...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
MRK
LISTED
NYSE
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
MRK
LISTED
NYSE
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in gynecologic cancers. The first approval is for KEYTRUDA, in combination with carboplatin and paclitaxel, for the first-line treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
MRK
LISTED
NYSE
CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines and recommends CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine)...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
MRK
LISTED
NYSE
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
MRK
LISTED
NYSE
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine), at IDWeek 2024 in Los Angeles, California. The trial evaluated the immunogenicity, safety and tolerability of CAPVAXIVE compared to PCV15 (pneumococcal 15-...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
MRK
LISTED
NYSE
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced its plans to present new research findings demonstrating the continued impact of its increasingly broad and diverse vaccines and infectious disease portfolio and the potential of its innovative pipeline at IDWeek 2024 in Los Angeles, CA, from October 16-19.
D...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
MRK
LISTED
NYSE
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) met...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
MRK
LISTED
NYSE
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
News Preview
NetworkNewsWire Editorial Coverage
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients su...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
